Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug GSK4771261 takes first step against inherited kidney disease

NCT ID NCT06734234

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests an experimental drug called GSK4771261 for safety and how the body processes it. Part A involves healthy volunteers, and Part B includes people with autosomal dominant polycystic kidney disease (ADPKD), a genetic condition that causes kidney cysts and can lead to kidney failure. Neither participants nor doctors know who receives the drug or a placebo. The goal is to see if the drug is safe enough to study further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called GSK4771261
What this could lead to
If safe and effective, GSK4771261 could point toward a new treatment for autosomal dominant polycystic kidney disease (ADPKD), a condition that often leads to kidney failure.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not on whether the drug works. Many drugs fail in early testing, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease impaired renal function disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY DISEASE

Contacts and locations

Locations

  • GSK Investigational Site

    Leuven, 3000, Belgium

  • GSK Investigational Site

    London, Ontario, N6A 5A5, Canada

  • GSK Investigational Site

    Toronto, Ontario, M5G 2C4, Canada

  • GSK Investigational Site

    Montreal, Quebec, H4J 1C5, Canada

  • GSK Investigational Site

    Brest, 29200, France

  • GSK Investigational Site

    Paris, 75015, France

  • GSK Investigational Site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • GSK Investigational Site

    Lübeck, Schleswig-Holstein, 23538, Germany

  • GSK Investigational Site

    Groningen, 9713 GZ, Netherlands

  • GSK Investigational Site

    Leiden, 2333 ZA, Netherlands

  • GSK Investigational Site

    Rotterdam, 3015 GD, Netherlands

  • GSK Investigational Site

    Barcelona, 08003, Spain

  • GSK Investigational Site

    Barcelona, 08025, Spain

  • GSK Investigational Site

    Barcelona, 08035, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Madrid, 28041, Spain

  • GSK Investigational Site

    Cambridge, CB2 0GG, United Kingdom

  • GSK Investigational Site

    Exeter, EX2 5DW, United Kingdom

  • GSK Investigational Site

    London, NW3 2QG, United Kingdom

  • GSK Investigational Site

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • GSK Investigational Site

    Rochester, Minnesota, 55905, United States

  • GSK Investigational Site

    Brussels, 1200, Belgium

  • GSK Investigational Site

    Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.